Cargando…
Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant
Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-1...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622241/ https://www.ncbi.nlm.nih.gov/pubmed/36285986 http://dx.doi.org/10.3201/eid2811.220577 |
_version_ | 1784821718071640064 |
---|---|
author | Quintero, Ana Maria Eisner, Mariah Sayegh, Rouba Wright, Tori Ramilo, Octavio Leber, Amy L. Wang, Huanyu Mejias, Asuncion |
author_facet | Quintero, Ana Maria Eisner, Mariah Sayegh, Rouba Wright, Tori Ramilo, Octavio Leber, Amy L. Wang, Huanyu Mejias, Asuncion |
author_sort | Quintero, Ana Maria |
collection | PubMed |
description | Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-19 outpatients and inpatients 0–21 years of age in Columbus, Ohio, USA, according to the infecting variant, identified using a mutation-specific reverse transcription PCR assay. Of the 676 patients in the study, 17.75% were infected with nonvariant strains, 18.49% with the Alpha variant, 41.72% with Delta, and 16.42% with Omicron. Rates of SARS-COV-2/viral co-infections were 15.66%–29.41% and were comparable across infecting variants. Inpatients with acute Delta and Omicron infections had lower SARS-CoV-2 cycle threshold values and more frequent fever and respiratory symptoms than those with nonvariant strain infections. In addition, SARS-COV-2/viral co-infections and the presence of underlying conditions were independently associated with worse clinical outcomes, irrespective of the infecting variant. |
format | Online Article Text |
id | pubmed-9622241 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-96222412022-11-05 Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant Quintero, Ana Maria Eisner, Mariah Sayegh, Rouba Wright, Tori Ramilo, Octavio Leber, Amy L. Wang, Huanyu Mejias, Asuncion Emerg Infect Dis Research Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-19 outpatients and inpatients 0–21 years of age in Columbus, Ohio, USA, according to the infecting variant, identified using a mutation-specific reverse transcription PCR assay. Of the 676 patients in the study, 17.75% were infected with nonvariant strains, 18.49% with the Alpha variant, 41.72% with Delta, and 16.42% with Omicron. Rates of SARS-COV-2/viral co-infections were 15.66%–29.41% and were comparable across infecting variants. Inpatients with acute Delta and Omicron infections had lower SARS-CoV-2 cycle threshold values and more frequent fever and respiratory symptoms than those with nonvariant strain infections. In addition, SARS-COV-2/viral co-infections and the presence of underlying conditions were independently associated with worse clinical outcomes, irrespective of the infecting variant. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622241/ /pubmed/36285986 http://dx.doi.org/10.3201/eid2811.220577 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Quintero, Ana Maria Eisner, Mariah Sayegh, Rouba Wright, Tori Ramilo, Octavio Leber, Amy L. Wang, Huanyu Mejias, Asuncion Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title_full | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title_fullStr | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title_full_unstemmed | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title_short | Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant |
title_sort | differences in sars-cov-2 clinical manifestations and disease severity in children and adolescents by infecting variant |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622241/ https://www.ncbi.nlm.nih.gov/pubmed/36285986 http://dx.doi.org/10.3201/eid2811.220577 |
work_keys_str_mv | AT quinteroanamaria differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT eisnermariah differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT sayeghrouba differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT wrighttori differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT ramilooctavio differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT leberamyl differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT wanghuanyu differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant AT mejiasasuncion differencesinsarscov2clinicalmanifestationsanddiseaseseverityinchildrenandadolescentsbyinfectingvariant |